At Nectara.ai, our vision is to empower clinicians and patients by translating breakthrough neuroimaging research into everyday clinical practice. Nectara PASCOM™ integrates FDG‑PET and MRI to detect metabolic asymmetries in the brain and accurately localize seizure‑generating tissue. Early clinical studies have shown that this method provides superior accuracy compared to conventional PET interpretation. By packaging these innovations into intuitive software, we aim to make advanced presurgical planning available to epilepsy teams everywhere and to give people living with drug‑resistant epilepsy a better chance at achieving seizure freedom.